Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 145 participants.

Also called NCT05001074

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 145 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05001074
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05001074. Randomized; no masking; primary purpose treatment. Start 2020-07-28 (actual); primary completion 2024-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients
Acronym
REVOLUTION
Condition
Lung Transplant; Complications
Intervention (Drug)
Extended release tacrolimus
Intervention (Drug)
Immediate release tacrolimus
Lead sponsor
Heleen Grootjans (class: other)
Collaborator
Chiesi Farmaceutici S.p.A. (class: industry)

Record details

Record id
cardio:ct-nct05001074
Content hash
63263b2927cb5b708f8f1a4cc6a6c0026c4c21599c731d21a4641c0c9e013d44